CF
ADCT icon

Corebridge Financial’s ADC Therapeutics ADCT Stock Holding History

Corebridge Financial’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-39,838
Closed -$56.2K – 47
2025
Q1 		$56.2K Sell
39,838
-592
-1% -$1.01K ﹤0.01% 2693
2024
Q4 		$80.5K Sell
40,430
-3,051
-7% -$7.98K ﹤0.01% 2657
2024
Q3 		$137K Buy
43,481
+5,815
+15% +$18.3K ﹤0.01% 2438
2024
Q2 		$119K Buy
+37,666
New +$150K ﹤0.01% 2493

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Corebridge Financial's ADCT Position: Q2 2025 in Review

Corebridge Financial sold out of ADC Therapeutics (ADCT) in Q2 2025, closing a stake of 39,838 shares — an estimated $56.2K sold.

Corebridge Financial first reported a position in ADCT in Q2 2024 and held it in 4 quarters. The position peaked at $137K in Q3 2024. 86 funds tracked by Wall St. Rank hold ADCT as of Q2 2025.

  • Corebridge Financial reported no remaining ADC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 39,838 ADC Therapeutics shares in Q2 2025, an estimated $56.2K.
  • Corebridge Financial first reported a position in ADC Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's ADC Therapeutics position peaked at $137K in Q3 2024.
  • 86 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.